AACR: Longer Survival With Gilteritinib in FLT3mut & #43; AML

MONDAY, April 1, 2019 -- For patients with FMS-like tyrosine kinase 3 (FLT3) mutations who have relapsed or refractory acute myeloid leukemia (AML), gilteritinib results in longer overall survival and higher response rates than salvage chemotherapy...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news